Quick Comparison
| Coluracetam | Noopept | |
|---|---|---|
| Half-Life | 2-3 hours | 30-60 minutes (active metabolite cycloprolylglycine persists longer) |
| Typical Dosage | Standard: 20-80 mg sublingually, 2-3 times daily. Start at 20 mg to assess sensitivity. Sublingual is strongly preferred for bioavailability. | Standard: 10-30 mg sublingually or orally, 2-3 times daily. Sublingual administration provides faster onset. Do not exceed 30 mg per dose. |
| Administration | Sublingual (strongly preferred) or oral. Oral bioavailability is limited. | Oral or sublingual (sublingual preferred for faster onset and higher bioavailability). Available as powder, capsules, or sublingual tablets. |
| Research Papers | 1 papers | 10 papers |
| Categories |
Mechanism of Action
Coluracetam
Coluracetam's primary mechanism is enhancement of high-affinity choline uptake (HACU) in hippocampal neurons — the rate-limiting step in acetylcholine synthesis. HACU is mediated by the high-affinity choline transporter (CHT1/SLC5A7), which coluracetam upregulates or potentiates, increasing the Vmax of choline transport into presynaptic terminals. By making this process more efficient, coluracetam increases acetylcholine production and vesicular packaging via the vesicular acetylcholine transporter (VAChT) even when choline levels are normal. This enhances cholinergic transmission in the hippocampus, cortex, and retina — explaining reports of enhanced color vision and visual acuity. Coluracetam also has minor AMPA receptor positive allosteric modulation. The compound was studied for treatment-resistant depression, possibly through cholinergic modulation of mood circuits.
Noopept
Noopept modulates AMPA and NMDA receptors similarly to racetams through positive allosteric modulation. Its key distinguishing feature is upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) via activation of TrkB and TrkA receptor signaling cascades — these neurotrophins are essential for neuronal growth, survival, dendritic arborization, and synaptic plasticity. Noopept inhibits glutamate-induced excitotoxicity by reducing calcium influx through NMDA receptors and modulating the NR2B subunit. It activates the PI3K/Akt and MAPK/ERK pathways downstream of neurotrophin receptors. The active metabolite cycloprolylglycine (a cyclic dipeptide) has endogenous nootropic activity, potentially acting as a trace amine-associated receptor ligand. Neuroprotection is further mediated through antioxidant effects and mitochondrial stabilization.
Risks & Safety
Coluracetam
Common
Headache, fatigue, brain fog at high doses.
Serious
Very limited human safety data — studied only in small trials.
Rare
Anxiety, irritability, suicidal ideation was reported in one clinical trial participant.
Noopept
Common
Headache (especially without choline supplementation), irritability at higher doses, brain fog in some users.
Serious
No serious adverse effects documented.
Rare
Emotional blunting at high doses, insomnia, allergic reactions.
Full Profiles
Coluracetam →
A racetam that enhances high-affinity choline uptake (HACU) — the rate-limiting step in acetylcholine synthesis. This makes it uniquely effective at boosting acetylcholine levels, which is why users commonly report enhanced color vision, sharper visual perception, and improved memory. It was briefly studied for treatment-resistant depression.
Noopept →
A synthetic peptide-derived nootropic often grouped with racetams due to similar effects, though it is technically a dipeptide analog of piracetam. Roughly 1000x more potent by weight than piracetam, requiring only 10-30 mg per dose. It provides both immediate cognitive enhancement and long-term neuroprotective benefits through BDNF and NGF upregulation.